GlassScriptPhysician profile
Tae J Chung
NPI 1922118306
$5,996.67
in general payments reported to CMS, 2019-2025
28 companies · $81.04 in 2025
The $81.04 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,639 · 2020: $454 · 2021: $1,092 · 2022: $313 · 2023: $150 · 2024: $267 · 2025: $81.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 108 LLC | $2,358.07 | 2019 | |
| Ucb, INC. | $866.10 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $559.10 | 2019-2022 | |
| Amgen INC. | $425.01 | 2019-2021 | |
| Janssen Biotech, INC. | $329.75 | 2019-2022 | |
| Glaxosmithkline, LLC. | $263.80 | 2019-2024 | Benlysta |
| Pfizer INC. | $259.45 | 2019-2021 | |
| Lilly USA, LLC | $125.82 | 2019-2021 | |
| Cardinal Health 110 LLC | $100.00 | 2021 | |
| Mallinckrodt Hospital Products INC. | $81.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $76.89 | 2019-2020 | |
| Horizon Therapeutics Plc | $63.03 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $53.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $51.07 | 2019 | |
| Genentech USA, INC. | $46.85 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $45.49 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $40.21 | 2021 | |
| Radius Health, INC. | $33.42 | 2019 | |
| Aurinia Pharma U.S., INC. | $33.11 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.82 | 2019-2020 | |
| Sobi, INC | $28.94 | 2019 | |
| Genzyme Corporation | $27.28 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $22.16 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $17.16 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.90 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.11 | 2021 | |
| Avion Pharmaceuticals | $13.63 | 2020 | |
| Celgene Corporation | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tae Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.